Investigation Report on China Rituximab Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||296864|
|出版日期||內容資訊||英文 30 Pages
|中國的Rituximab市場分析 Investigation Report on China Rituximab Market, 2010-2019|
|出版日期: 2015年05月28日||內容資訊: 英文 30 Pages||
Rituximab (trade name is Rituxan by Roche) was a human-mouse chimeric anti-CD20 monoclonal antibody approved by FDA to treat tumor in 1997. The treatment range of Rituximab extends from B-cell malignant tumors to rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura and such autoimmune diseases. In 2014, the sales revenue of Rituxan exceeded USD 8 billion.
In China, the incidence of non-Hodgkin lymphoma fast rises from 20/1 million at the end of 20 century to 70/1 million nowadays. Autoimmune diseases can harm central nervouos system and organs such as lung, liver and kidney, leading to organ dysfunction and even organ failure. All of them can be life threatening. Statistics shows that there are approximately 30 to 40 million people suffering from autoimmune diseases in China. Such incidence is high enough to attract people's attention.
By the second quarter of 2015, there is no Rituximab produced by Chinese domestic enterprise on the market. The market is wholly occupied by products of Roche. Early 2014, monoclonal antibody drug "recombinant human-mouse chimeric anti-CD20 monoclonal antibody injection" produced by Hisun was approved clinical. It is generic drug of Rituximab of Roche. Five manufacturers in China have reported clinical use of rituximab generic drug. It is estimated that more generic drugs will go on the market in the next few years. According to CRI's investigation on certain sample hospitals in China, the CAGR of sales value of rituximab surpassed 30% from 2005 to 2014. Rituximab is expected to have huge room to grow in future Chinese market.
Through this report, the readers can acquire the following information:
The Following Enterprises and People Are Recommended to Purchase This Report: